Abstract #300394

This is the preliminary program for the 2003 Joint Statistical Meetings in San Francisco, California. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 2-5, 2003); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.


Back to main JSM 2003 Program page



JSM 2003 Abstract #300394
Activity Number: 6
Type: Invited
Date/Time: Sunday, August 3, 2003 : 2:00 PM to 3:50 PM
Sponsor: Section on Bayesian Stat. Sciences
Abstract - #300394
Title: Bayesian Applications in Medical Device Clinical Trials
Author(s): Andrew S. Mugglin*+ and H. Amy Xia*+
Companies: Amgen, Inc. and Medtronic, Inc.
Address: 7000 Central Ave., NE, Minneapolis, MN, 55432-3568, 24-2-A, Thousand Oaks, CA, 91320-1730,
Keywords: medical device clinical trials ; hierarchical modeling ; sequential monitoring ; multiple outcomes
Abstract:

Medical device clinical trials are unique in the sense that a great deal of historical information on similar devices often exists, or sometimes a staged clinical strategy is taken in the new product development process. A Bayesian hierarchical approach is very suitable for such settings because by using good prior information, the size of a trial can be reasonably reduced. Other advantages of using Bayesian methods include sequential monitoring, prediction, and random effects modeling. Several case studies will be presented. One involves hierarchical modeling with borrowing of information from previous studies and faces some modeling challenges when the parameter of interest is on the edge of the parameter space. Another study features sequential monitoring of multiple safety and efficacy outcomes, while incorporating risk-benefit assessment into the stopping rules. In addition, practical challenges when planning a Bayesian trial in a regulatory setting will be addressed.


  • The address information is for the authors that have a + after their name.
  • Authors who are presenting talks have a * after their name.

Back to the full JSM 2003 program

JSM 2003 For information, contact meetings@amstat.org or phone (703) 684-1221. If you have questions about the Continuing Education program, please contact the Education Department.
Revised March 2003